Clinical Trial Search

Primary: Visuospatial Problem Solving Battery (VSP) — .30; .29; .097; .52 Mean Difference Score (VPS Total Score)

Primary: Change From Baseline for Average Pain Intensity as Measured by the NRS — -1.57; -2.09 score on a scale

Primary: Proportion of Neonate Survival at Discharge From Hospital — 1; 3 Participants

Primary: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) — 3; 2; 1; 59 Participants

Primary: Number of Participants With at Least One Dose Limiting Toxicity (DLT) — 2; 0 participants

Primary: Change in Ménière's Vertigo Attack Frequency Between Lamotrigine and Placebo Group — 18.88; 18.00; 13.50; 4.57 Average Total Number of Vertigo Attacks — p=0.5618

Primary: Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration — 0; 0; 0; 0 Number of DLTs

Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients

Primary: Immune Response Measured by IFN-gamma Secreting PBMC Precursor Frequency by ELIspot and HLA-A2 Major Histocompatibility Complex Tetramer Analysis — 14; 4; 1; 16…

Primary: L-citrulline Plasma Levels — 200.9; 34.1; 2405.9; 29.5 µmol/L

Primary: Sensitivity of OTL38 in Detecting Folate Receptor-alpha Positive Ovarian Cancer During Surgery. — 97.97 percentage of lesions

Primary: Time to Sustained Improvement of at Least 2 Categories on 6-point Ordinal Clinical Recovery Scale (CRS): Primary Analysis Set — 17.00; 23.00 Days

Primary: Number of Asthma Exacerbations During the Treatment Period — 0.96; 1.30 Exacerbations during treatment — p=0.027

Primary: Dihydrotestosterone (DHT) Concentration in Benign Prostate Tissue After a Combination Drug Treatment Based on Genotype Status — 9.066; 5.917; 9.345 nM

Primary: Wave Reflection Magnitude — 0.38; 0.44; 0.37 dimensionless ratio